Earnings Feed
Start Free
ADMA BIOLOGICS, INC.·4

Feb 11, 9:00 PM ET

Grossman Adam S 4

4 · ADMA BIOLOGICS, INC. · Filed Feb 11, 2026

Research Summary

AI-generated summary of this filing

Updated

ADMA (ADMA) CEO Adam Grossman Receives 282,529 RSUs

What Happened
Adam S. Grossman, President, CEO and Director of ADMA Biologics, received equity awards on February 9, 2026: 282,529 restricted stock units (RSUs) reported as an award (price $0) and 444,711 RSU-related derivative units reported separately. These RSUs are unvested awards that will settle into common stock upon vesting; no cash was paid for the grants.

Key Details

  • Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely).
  • Reported entries: 282,529 RSUs (Award, A) and 444,711 RSU-related derivative units (A); transaction price shown as $0.00.
  • Vesting: New RSUs vest quarterly over four years from grant date (per the ADMA 2022 Equity Compensation Plan). All listed RSUs settle into common stock upon vesting.
  • Shares owned after transaction: 975,684 shares of common stock (reported) plus approximately 1,314,695 unvested RSUs across grants (breakdown by grant year in filing: 282,529 [2026], 252,022 [2025], 418,296 [2024 portion], 286,848 [2023 portion], 75,000 [2022 portion]).
  • Related roles/ownership: Grossman is a control person of Areth, LLC and managing member of Hariden, LLC (both referenced in footnotes as holders of company shares).
  • Options note: The filing also references outstanding options that vest over four years (25% after one year, then monthly), becoming fully vested on Feb 9, 2030.
  • Filing status: Timely (no late filing indicated).

Context
This was an equity award (RSUs), not an open-market purchase or sale—awards are common compensation for executives and do not represent an immediate cash purchase or sale. RSUs are derivative securities that convert to shares only as they vest; they can signal continued alignment with shareholders but do not by themselves indicate buying or selling intent.

Insider Transaction Report

Form 4
Period: 2026-02-09
ADMA BIOLOGICS, INC.ADMA
Grossman Adam S
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    [F1][F2][F3][F4]
    2026-02-09+282,529→ 2,290,379 total
  • Award

    Stock Option (right to buy)

    [F7]
    2026-02-09+444,711→ 444,711 total
    Exercise: $16.37Exp: 2036-02-09→ Common Stock (444,711 underlying)
Holdings

  • Common Stock

    [F5]
    (indirect: See Footnote)
    1,143,426

  • Common Stock

    [F6]
    (indirect: See Footnote)
    580,957
Footnotes (7)
  • [F1]These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
  • [F2]Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F3](continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F4](continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  • [F5]These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  • [F6]These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  • [F7]The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.
Signature
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact|2026-02-11

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4